Topical antacid therapy for capsaicin-induced dermal pain: a poison center telephone-directed study by Kim-Katz, Susan Y. et al.
www.elsevier.com/locate/ajem
American Journal of Emergency Medicine (2010) 28, 596–602Original Contribution
Topical antacid therapy for capsaicin-induced dermal pain:
a poison center telephone-directed study
Susan Y. Kim-Katz Pharm Da,b,⁎, Ilene B. Anderson Pharm Da,b,
Thomas E. Kearney Pharm Da,b, Conan MacDougall Pharm Da,
Karen S. Hudmon DrPH, MS, BSPharmc,1, Paul D. Blanc MD, MSPHb,d
aDepartment of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143-1369, USA
bCalifornia Poison Control System, San Francisco Division, San Francisco, CA 94143-1369, USA
cSchool of Pharmacy & Pharmaceutical Sciences, Purdue University, West, Lafayette, IN 47907-2103, USA
dDivision of Occupational and Environmental Medicine, University of California, San Francisco, CA 94143-4924, USA
Received 5 December 2008; accepted 10 February 2009Abstract
Purpose: The study aimed to assess the effects of topical antacids for treatment of capsaicin-induced
dermal pain after exposure to capsaicin containing hot peppers, personal protection sprays, or
topical creams.
Procedures: Participants of the study were California Poison Control System (CPCS) hotline callers
12 years or older with dermal pain from exposure to capsaicin-containing products or plants.
Participants were instructed to apply a topical antacid and assessed for perceived pain (using a 0-10
scale) pre- and posttreatment. A positive response was defined as a sustained reduction of pain 33%
or more within 30 minutes or achieving a pain score of 0 to 1.
Main findings: Of 93 eligible patients, 64 applied antacids and had outcome data available. Patients
contacted the CPCS a median of 1 hour postexposure with a median initial pain score of 7.5/10.
Thirty-six (56%) were exposed to unrefined (natural) peppers and 28 (44%) to refined capsaicin (eg,
capsaicin-containing cream). Before calling the CPCS, 57 (89%) attempted at least one treatment.
Forty-five (70%) reported positive response to antacid treatment as a 33% reduction in pain in 30
minutes (n = 17), a reduction in pain to a score of 0 to 1 (n = 3), or both (n = 25). A 33% reduction
in pain within 30 minutes was associated with exposure to refined capsaicin (odds ratio, 3.37; 95%
confidence interval, 0.98-11.66). Concomitant refined capsaicin exposure and early treatment (b1
hour of symptoms) was associated with even greater odds of response (odds ratio, 5.4; 95%
confidence interval, 1.4-21.2).The study findings were presented as a poster at the 2002 North American Congress of Clinical Toxicology conference in Palm Springs, Ca. In conjunction
with this meeting, the findings were published in abstract form in the Journal of Toxicology-Clinical Toxicology [Kim SY, Anderson IB, Kearney TE. A
prospective study evaluating the effectiveness of liquid antacid application for the treatment of capsaicin-induced dermatitis. (Abstract 56) J Toxicol-Clin
Toxicol. 2002;40(5):621-622].
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Capsaicin, the pungent, active compound in the Caspi-
cum plant genus, is found in several varieties of hot peppers.
It is used in foods as a flavoring agent, in personal protection
sprays and animal repellents, and in topical creams and
ointments for the treatment of chronic pain. Dermal exposure
of capsaicin affects cutaneous sensory neurons, inducing
burning, redness, irritation, and pain that sometimes can be
excruciating and last for hours to days after exposure [1].
Symptomatic exposures to capsaicin are common. In
2005, the American Association of Poison Control Centers
reported 4377 exposures to “capsicum defense sprays” and
5305 exposures to “capsicum/peppers.” [2] Capsaicin-
containing topical treatments were not reported as a distinct
category in these data, and thus, any adverse reports due to
such products were presumably included in the latter group.
A variety of topical treatments to alleviate the symptoms of
capsaicin exposure have been suggested in the medical
literature as well as on Internet sources [3-7]. These include
milk, bleach, ice water, vinegar, and vegetable oil. A study of
vegetable oil application vs cool water found that although
cool water immersion initially provided more relief,
vegetable oil provided better long-term relief from “chile
burns” of the hands [5]. None of these treatments, however,
effectively results in prompt, sustained pain relief. Local
anesthetics offer relief for some patients but are rarely
accessible in the home [3].
In 1998, Herman and colleagues [8] described 7 patients
who had severe dermal discomfort secondary to a “pepper-
mace” exposure. Within minutes after the application to the
affected area of Liquid Maalox (ingredients: magnesium
hydroxide and aluminum hydroxide), the patients were
completely pain-free. In a recent double-blind randomized
controlled trial, 10 volunteers were sprayed with 10%
capsaicin on both forearms simultaneously. One arm was
treated with Maalox, the other arm with saline. The Maalox
treatment resulted in significant reductions in perceived pain
(10-point visual analog scale) at 10, 20, and 30 minutes; at
60, 90, and 120 minutes, pain in the treated arm was also
reduced compared to the control arm, but these reductions
were not statistically significant [9]. Another controlled
study (presented as an abstract only), however, comparing
Maalox, lidocaine, baby shampoo, milk, and water for
treatment of pepper spray exposures found no differences in
pain among the treatment groups [10]. We report our
experiences with topical antacid application for capsaicin-
induced dermal pain among a typical population with
symptoms troubling enough to prompt a phone consultation
with a poison control center.2. Methods
2.1. Study design
We conducted an observational clinical study of topical
antacid application for treatment of dermal capsaicin
exposures using a convenience sample of cases serially
contacting the telephone hotline of the California Poison
Control System (CPCS), San Francisco, for consultation.
Cases meeting a priori inclusion criteria were followed and
analyzed prospectively. The study was approved by the
Committee on Human Research at the University of
California, San Francisco.
2.2. Setting
The CPCS is a 24-hour emergency telephone consultation
service whereby licensed specialists in poison information or
poison information providers evaluate poisonings and
provide treatment advice to health care professionals and
the lay public. The CPCS fields more than 200 000 calls
related to human exposures annually. For each consultation,
a computerized record is generated in accordance with
criteria established by the American Association of Poison
Control Centers. Study participants were recruited from
callers to the CPCS who reported dermal exposure to
capsaicin over the 15 month period between January 2001
and April 2002.
2.3. Selection of participants
Patients eligible for participation in the study met the
following inclusion criteria: (1) self-reported history of
dermal exposure to a capsaicin-containing material, (2)
dermal symptoms consistent with contact of capsaicin on
intact skin (ie, not abraded), (3) ability to assess and
categorize discomfort using a 0 to 10 pain scale, (4) 12 years
or older. We limited inclusion to persons 12 years old or older
because we anticipated that persons younger than this would
be unable to evaluate and report accurately their discomfort
using the 0 to 10 pain scale, thus leading to unacceptable
measurement error in a key study variable. Patients were
excluded from the outcome analysis for the following
reasons: (1) antacids were not used after contact with
CPCS despite a recommendation to do so; (2) patients lost to
follow-up (wrong phone number provided or unable to reach
after repeated attempts); and (3) otherwise eligible patients
not formally enrolled by the CPCS staff and were therefore
missing key study variables.
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We classified the capsaicin exposure according to its
source: either unrefined capsaicin (peppers such as jalapeño,
red chili, or habañero) or refined capsaicin (as contained in
personal protection sprays (eg, “pepper spray,” animal
repellents, or a cream or ointment [eg, Zostrix cream]). We
did not have any quantifiable measurements of capsaicin
content available for most sources. For example, we did not
attempt to collect the peppers and measure their capsaicin
content in “Scoville Heat Units” nor did we solicit a
subjective assessment from study participants as to the
“hotness” of the pepper involved.
2.5. Treatment interventions
For the purposes of this study, antacids were defined as
any divalent cation-containing product, such as antacids that
contain calcium or magnesium (eg, Maalox, Mylanta, Milk
of Magnesia [marketed as both a laxative and an antacid]) or
antacid tablets (eg, Tums). Patients agreeing to participate in
the study were advised to apply or soak the affected area
liberally with a room-temperature antacid product as defined
above. If only antacid tablets (eg, Tums) were available, the
patient was advised to crush the tablets, create a slurry by
mixing the crushed material with water, then apply to or soak
the affected area with this slurry. Patients without access to,
or unwilling to use, the antacids listed above were advised to
apply other treatments cited in previous publications, such as
ice water, milk, vegetable oil, baking soda, or local
anesthetics. These non-antacid treatments were not included
in the outcomes analysis.
2.6. Study measures
At the initial assessment, standard CPCS case data
collection procedures recorded age, sex, product involved,
time elapsed since exposure, and symptoms experienced. All
data were entered as a case record, with a unique case
identifier, in accordance with CPCS policies and protection
of caller confidentiality. Once study eligibility was estab-
lished, the CPCS staff informed the patient (or the parent/
guardian of those 12-18 years of age) of the study and read a
scripted verbal consent. Once consent for participation was
obtained, each study participant was asked: (a) “What
treatments have you already tried?” and (b) “How would you
rank your pain currently on a scale of 0 (no pain) to 10 (worst
pain ever experienced)?” The 0- to 10-point pain scale has
been validated previously for assessment of pain through
telephone interviews [11]. An initial follow-up telephone call
was attempted within 2 hours of the initial consultation to
allow time for procurement of an antacid if not readily
available as well as time for treatment application and
assessment of outcome. At follow-up, patients were asked:
(a) “What treatments did you use after calling the CPCS?”(b) “How would you rank your pain after the treatment on a
scale of 0 (no pain) to 10 (worst pain ever experienced)?” and
(c) if the treatment was beneficial, “How long did the therapy
take to work?”
Consistent with previously published pain assessments, a
positive response to treatment was defined as a sustained
reduction in the pain scale ranking of at least 33% within 30
minutes [12-15]. In addition, a positive response was also
defined as “resolution of pain” based on a pain scale ranking
of 0 or 1 post antacid therapy. If pain relief was not sustained,
the treatment was classified as ineffective and excluded from
the outcome analysis. For example, if a patient experienced
at least a 33% reduction in the pain scale rating within 30
minutes of ice water immersion, but the pain returned
promptly upon removal of the affected area from the ice
water, the treatment was deemed ineffective.
2.7. Data analysis
We compared the characteristics of study subjects who
were included in the analysis of the outcomes of antacid-
treated patients to those who were excluded using the χ2 test
and unpaired t test or Wilcoxon rank sum test, as appropriate.
For subjects included in the antacid outcome analysis, we
compared pre- to posttreatment pain levels using the paired t
test for pain score as a continuous variable. To reduce the
potential confounding effects of multiple treatments, only
those subjects who used antacids as the initial treatment after
CPCS contact were included in the analysis for antacid
treatment. We further studied pain response using 2 other
measures derived from the continuous scores: a 33%
reduction in pain within 30 minutes or achieving a
posttreatment pain score of 0 to 1. The former measure of
response (a 33% pain reduction) was considered the primary
study outcome (dependent variable). Exposure and treatment
variables as potential predictors (independent variables)
associated with this outcome were investigated using logistic
regression analysis. We chose these variables a priori and
tested separately in a series of simple logistic models.
Reported P values are from standard χ2 analysis, except for
the analysis of response according to baseline pain score for
which we performed a χ2 test for trend. After these bivariate
analyses, we tested a multivariable logistic regression model
by using a forward stepwise approach (chosen because of the
relatively small sample size). We first entered into the model
the strongest predictor of response from the bivariate
analysis (capsaicin source). Additional variables were
incorporated into the model, beginning with the next
strongest predictor of response, and were retained in the
model if (1) they showed a statistical association as an
independent predictor of outcome using a P b .10 α value for
inclusion and if (2) they were potential confounders of the
effect of other variables (based on modification of the point
estimate of the odds ratio [OR] in the previous bivariate
modeling). In addition, we tested for interactions between
source of capsaicin and time until contact with poison center
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model along with those 2 measures and by estimating the
association between the risk factors combined relative to
their absence. Finally, “survival data” (ie, time until
resolution of pain) were analyzed using a Cox proportional
hazards model including the same predictors as were used in
the multivariate logistic regression. Follow-up time was
censored at 2 hours.3. Results
3.1. Study population
Of the 93 patients who were eligible for the study, 29 were
excluded for analysis of antacid outcome according to the
criteria previously described. Of the 29 excluded, 19 did not
use antacids, 7 were unable to be contacted for the follow-up
assessment (wrong telephone number or unable to reach
despite repeated attempts), and 3 were not properly enrolled
by the CPCS staff. This yielded a sample size of 64
participants (68% of the eligible population) for the antacid
outcome analysis. Of the 64 subjects, 8 were treated at a
health care facility. Table 1 describes the characteristics of
the study participants, according to whether they were
included in the analysis of antacid outcome. In both groups,Table 1 Characteristics of capsaicin-exposed patients by analysis gro
Participant characteristics Included in an
(n = 64)
Demographics
Sex (n [%])
Female 49 (76.6)
Male 15 (23.4)
Age in years (mean [SD]) 34.5 (14.4)
Exposure and treatment
Capsaicin source (n [%])
Natural peppers 36 (56.3)
Refined products 28 (43.7)
Any pretreatment before call (n [%])
Pretreatment 57 (89.1)
No pretreatment 7 (10.9)
No. of pretreatments (median [range]) 1 (0-5)
Antacid cations used (n [%])
Both magnesium and aluminum 44 (68.7)
Other cations 20 (32.3)
Pain characteristics
Duration of pain before call (n [%])
≤1 h 36 (56.2)
N1 h 28 (43.8)
Pain duration in hours (median [range]) 1 (0.08-24)
Baseline pain score (median [range]) 7.5 (1.5-10)
Final pain score (median [range]) 2 (0.5-5.25
a n = 28, data missing for 1 subject.
b n = 25, data missing for 4 subjects.most patients were female, and the mean age was
approximately 35 years. Unrefined capsaicin (ie, natural
peppers) was responsible for most of the capsaicin exposures
(36/64, 56%) in the outcome analysis group, whereas
subjects excluded from analysis were exposed to refined
capsaicin more commonly (18/29, 62%), although this
difference was not statistically significant (P = .10). The
median pain score at baseline was higher in the included
subjects compared to those who were excluded (7.5 vs 6.0,
respectively; P = .03). Duration of pain, defined as elasped
time between exposure and contact with the CPCS, was less
than 1 hour for most callers in both groups and did not differ
statistically on this basis.
3.2. Treatment characteristics
In both included and excluded subjects, approximately
90% (57/64 and 26/29, respectively) had attempted at least
one treatment before calling the CPCS. The most frequently
used pretreatments by the included subjects were cold
water/ice (39), soap (24), milk (11), and baking soda (7).
Among the CPCS-recommended antacid treatments
included in the outcome analysis, 44 (68%) of 64 of the
antacids contained aluminum and magnesium, with the
remainder containing magnesium, aluminum, and calcium
(either alone or in combination).up
alysis Excluded from analysis
(n = 29)
P
.26
19 (65.5)
10 (34.5)
35.6 (12.9) .73
.10
11 (37.9)
18 (62.1)
.93
26 (89.7)
3 (10.3)
1 (0-3) .11
Not applicable
Not applicable
.94
16 (57.1) a
12 (42.9)
0.6 (0.08-13) .56
6 (2.5-10) b .03
) Not applicable
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The median final pain score across the 64 subjects
analyzed for outcomes was 2 of a maximum possible score of
10. The mean change in pain scores was a 4.2-point decrease
from the initial pain score (P b .0001; 95% confidence
interval [CI], 3.3-5.0). Overall, 45 patients (70%) reported a
positive response as a 33% reduction in pain within 30
minutes (17 patients), a reduction in pain to a score of 0 to 1
(3 patients), or both (25 patients). For the 28 patients who
reported a reduction in pain score to 0 to 1, the mean time to
reach that pain level was 16 minutes, ranging from 1 minute
(immediate relief) to 60 minutes.3.4. Predictors of response
Table 2 represents an analysis of the response to antacid
therapy, specifically the association between study participant
characteristics and 33% reduction in pain within 30minutes of
treatment. As shown, exposure to refined capsaicin products
(as opposed to unrefined material, eg, chili peppers) was
associated with a statistically significant greater likelihood of
pain reduction response, with a marginally statistically
significant increased odds of response seen among those
with pain duration of one hour or less before calling the
CPCS. The duration of pain before calling the CPCS differed
significantly by capsaicin source. For those exposed to
unrefined capsaicin, 61% (22/36) waited an hour or more
before contacting the CPCS, whereas, in contrast, of those
exposed to refined capsaicin products, only 22% (6/28) waited
an hour or more (P = .002). We identified a difference in pain
relief among different antacid formulations. Of the 44 patientsTable 2 Response to topical antacid therapy among 64 treated cases
Predictors of pain reduction 33% Pain reduction wit
Yes
All participants 42 (65.2%)
Capsaicin source
Unrefined 19 (52.8%)
Refined 24 (82.1%)
Pain duration before call
N1 h 15 (53.5%)
≤1 h 27 (75.0%)
Baseline pain score quartile
Lowest (1.5-5) 10 (58.8%)
Moderate (5.5-7.5) 10 (55.6%)
High (8-8.5) 9 (69.2%)
Highest (9-10) 13 (81.2%)
Any pretreatment before call
No pretreatment 5 (71.4%)
Pretreatment 37 (64.9%)
Antacid cation
Other cations 11 (55.0%)
Both magnesium and aluminum 31 (70.5%)who used antacids containing magnesium and aluminum,
70.5% reported a 33% reduction within 30 minutes compared
to 55% for those using other preparations (a nonstatistically
significant difference).
Multivariable logistic regression was used to analyze the
independent effects of these variables on outcome. Type of
cation administered and baseline pain score did not have
statistically significant independent associations with out-
come or act as substantial confounders of the relationship
between capsaicin type and outcome and were thus excluded
from the model. Duration of pain less than an hour before
treatment did not have an independent effect on outcome but
attenuated the effect of capsaicin type. Exposure to refined
capsaicin was marginally associated with increased like-
lihood of response after adjustment for pain duration (P = .05;
OR, 3.37; 95% CI, 0.98-11.66). There was no evidence for
statistical interaction between capsaicin type and duration of
pain before calling CPCS when an interaction term was
included in the model (interaction term P = .54). Using a
separate analytic approach, odds of response were similar in
the groups exposed to refined capsaicin products whether
they experienced greater than (OR, 6.0; 95% CI, 0.6-60) or
less than an hour of pain before calling (OR, 5.4; 95%CI, 1.4-
21.2) relative to the group exposed to unrefined products with
greater than an hour of pain (the reference group). In the
group exposed to unrefined capsaicin for less than an hour
before calling, odds of a positive response were 2.2 times
(95%CI; 0.5-8.6) the odds of response in the reference group.
The time to reduction in pain to a score of zero to one was
further analyzed using a Cox proportional hazards model. No
patient or treatment characteristics were statistically sig-
nificant predictors of response in bivariate analyses (data not
shown) or in a multivariable analysis using the samefollowed for pain response: results of logistic regression analysis
hin 30 min OR (95% CI) P
No
22 (34.8%) N/A N/A
.01
17 (47.2%) 1.0 (Referent)
5 (17.9%) 4.11 (1.28-13.2)
.07
13 (46.5%) 1.0 (Referent)
9 (25.0%) 2.6 (0.90-7.49)
.12
7 (41.2%) 1.0 (Referent)
8 (44.4%) 0.88 (0.23-3.34)
4 (30.7%) 1.56 (0.34-7.22)
3 (18.8%) 3.03 (0.62-14.78)
.73
2 (28.6%) 1.0 (Referent)
20 (35.1%) 0.74 (0.13-4.01)
.23
9 (45.0%) 1.0 (Referent)
13 (29.5%) 1.95 (0.65-5.82)
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regression (male sex, exposure to refined capsaicin, baseline
pain score).4. Discussion
Capsaicin is an excitatory substrate for the nociceptors
(noxious stimuli detectors) of sensory neurons. Stimulation
of these primary afferent fibers results in an influx of cations,
which initiates action potential firing and subsequent release
of neurotransmitters from central terminals in the spinal cord
to generate acute pain. Activation also leads to release of
proinflammatory peptides such as substance P and calcitonin
gene–related peptide from the peripheral terminals of these
afferent neurons, promoting vasodilation, vascular leakage,
and inflammation [16,17]. An important hallmark of this
cascade of events is local tissue acidosis. After repeated
exposure to capsaicin, the receptors become desensitized,
resulting in a lack of excitatory response to capsaicin and
certain other painful stimuli. This desensitization is the basis
for using topical capsaicin for treatment of chronic pain. The
onset and extent of desensitization depends on many factors,
including the dose and intervals between applications [17].
The activation of capsaicin-sensitive nociceptors is
potentiated by high temperature and low pH [16]. Cool
temperature may attenuate the calcitonin gene-related
peptide–mediated vasodilation. Consistent with this
mechanism, some of our hotline callers reported that soaking
the affected skin area in cold liquids provided immediate
pain relief, but only as long as they continued this treatment.
The increased stimulation of nociceptors by protons has
obvious implications for antacid therapy. In vitro studies
suggest that extracellular protons increase the probability of
receptor channel opening [16]. It is possible that antacids
provide pain relief by raising extracellular pH, thereby
decreasing receptor sensitivity.
The effect of antacids might also be due to the presence of
divalent cations, particularly Ca2+ and Mg2+. The perme-
ability of the capsaicin-operated inward current during
depolarization of the afferent neurons is greatest for Ca2+
and Mg2+. In in vitro studies, removal of extracellular Ca2+
enhances the excitatory action of capsaicin [17]. Thus,
providing Ca2+ and Mg2+ externally may suppress the
actions of capsaicin. Nonetheless, whether these cations can
interact with capsaicin-sensitive nociceptors across intact
skin is unclear. In our study, of those who used antacids, 69%
used a combination product containing magnesium and
aluminum. Although not statistically significant, 70.5% of
those using this combination reported a 33% reduction
within 30 minutes compared to 55% for those using other
preparations. Whether trivalent cations such as aluminum
have a role in reducing pain from capsaicin can be a subject
for further study.
We observed a greater likelihood of pain improvement
measured as a 33% reduction in 30 minutes or less (althoughnot a more rapid time until complete resolution) among those
exposed to refined as opposed to unrefined capsaicin. This
may be explained by a higher exposure level or skin
penetration of capsaicin from unrefined sources (ie, from hot
peppers rather than capsaicin containing sprays or creams),
but we cannot formally test these hypotheses in this analysis.
As discussed in the Introduction, there are conflicting
reports in the medical literature regarding the utility of
topical antacid treatment of capsaicin exposures [8-10]. To
our knowledge, ours is the largest study to examine the
therapeutic effect of antacids for dermal capsaicin exposure.
This study setting provides a feasible methodology and “real-
world” experience base. However, this methodology placed
several constraints on our experimental study design,
including the inability to blind observers and study
participants (thus being unable to control for placebo
effects), randomize subjects to treatment arms, indepen-
dently confirm treatment applications (because the study was
dependent on subject self-reporting), or assess pain using a
visual analog scale. Other limitations to the study include a
lack of a “wash-out period” between the treatment methods,
many of which were initiated by patients before calling the
CPCS. Furthermore, we did not document dermal areas of
exposure, address chronic skin conditions, or ascertain the
concentrations of capsaicin in products, all of which could
have affected responsiveness to antacid treatment. In regard
to capsaicin content specifically, even if it had been possible
to identify the specific species of peppers, this would have
provided qualitative data at best. The “hotness” in peppers is
measured by Scoville heat units, a subjective taste test that
depends on the individual taste sensitivity. Although
capsaicin concentrations can be determined by sophisticated
laboratory analysis techniques, such methods are limited to
the food industry [18]. Quantification for personal defense
sprays presents similar difficulties: the oleoresin capsicum
(OC) concentration reported does not measure the actual
concentration of capsaicin in the formulation, which varies
with the species of the pepper used in the product (eg, a
product containing 5.5% OC can contain 5 times that amount
of capsaicin, as assayed by high-performance liquid
chromatography, as the amount found in a 10% OC product)
[19]. Despite these limitations noted above, our findings do
indeed support the use of an easily available self-treatment
with a negligible risk-profile to alleviate pain due to a very
common source of household exposures.
Application of topical antacids for capsaicin-induced
dermal pain is a safe, inexpensive, and reasonable treatment
approach of a frequent and often excruciating problem.
Antacids may be particularly useful for early treatment of
dermal exposure to refined capsaicin products.Acknowledgment
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